3 not yet recruiting, 2 recruiting, 1 completed. 2 Phase 4, 1 Not applicable, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 2 | Completed 1, Not yet recruiting 1 |
| Not applicable | 1 | Recruiting 1 |
| Phase 2 | 1 | Recruiting 1 |
Follow Hepato Cellular Carcinoma: new trials by email Literature Review of Hepato Cellular Carcinoma trials Research Report on Hepato Cellular Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Inter-Individual Tumor Heterogeneity on 3D-MRE for Predicting Response to Conversion Therapy in Liver Cancer Three-Dimensional Magnetic Resonance Elastography - Hepato Cellular Carcinoma, Intrahepatic Bile Duct Carcinoma | Not yet recruiting | Second Affiliated Hospital of Xi'an Jiaotong University | 100 | 2026-10-01 | 2026-07-21 | |
| Ebastine for Adjuvant Treatment of Tumor Budding-Positive Liver Cancer After Surgery Ebastine - Hepato Cellular Carcinoma | Phase 4 | Not yet recruiting | Second Affiliated Hospital of Xi'an Jiaotong University | 45 | 2026-10-01 | 2026-07-29 |
| Peritumoral MRE Stiffness for Predicting Resection Margin Status and Recurrence in Liver Cancer Three-Dimensional Magnetic Resonance Elastography - Hepato Cellular Carcinoma, Intrahepatic Bile Duct Carcinoma | Not yet recruiting | Second Affiliated Hospital of Xi'an Jiaotong University | 150 | 2026-08-01 | 2026-07-15 | |
| PSYLIVER-PILOTE: Involvement of the Autonomic Nervous System in Hepatocellular Carcinoma (HCC) Measurements of autonomic nervous system (ANS) activity at rest and during sensory stimulation., Self-administered questionnaires to assess psycho-behavioral traits, Analysis of nocturnal cardiac activity (at home): electrocardiographic (ECG) recording of heart activity during one night. - Hepato Cellular Carcinoma, Cirrhosis | Not applicable | Recruiting | Hospices Civils de Lyon | 100 | 2026-04-17 | 2026-04-29 |
| IIT2025-03-YANG-LIFT-HCC STRIDE Regimen (Tremelimumab 300 mg AND Durvalumab 1500 mg) combined with LRT (TACE, TARE, or RFA) - Hepato Cellular Carcinoma | Phase 2 | Recruiting | Ju Dong Yang | 41 | 2026-04-01 | 2026-03-27 |
| Kinectics of Distribution of Doxorubicin-Lipiodol Emulsion in c-TACE Super selective transarterial chemoembolization of CHC, with doxorubicin reconstituted in 5cc iso-osmolar ionic iodinated contrast media, Super selective transarterial chemoembolization of CHC, with doxorubicin reconstituted in 5cc normal saline - Hepato Cellular Carcinoma | Phase 4 | Completed | University Hospital, Strasbourg, France | 10 | 2018-11-26 | 2026-06-05 |
Carcinoma, Hepatocellular (2) · Cholangiocarcinoma (2) · Fibrosis (1)
Adenocarcinoma (2) · Carcinoma (2) · Digestive System Diseases (2) · Digestive System Neoplasms (2) · Liver Diseases (2) · Liver Neoplasms (2) · Neoplasms (2) · Neoplasms by Histologic Type (2) · Neoplasms by Site (2) · Neoplasms, Glandular and Epithelial (2) · Pathologic Processes (1) · Pathological Conditions, Signs and Symptoms (1)
durvalumab (1) · ebastine (1) · epicatechin gallate (1) · tremelimumab (1)
Second Affiliated Hospital of Xi'an Jiaotong University (3) · Hospices Civils de Lyon (1) · Ju Dong Yang (1) · University Hospital, Strasbourg, France (1)
France (2) · United States (1)
2018 (1)